ICCC ImmuCell Corporation
Healthcare$10.12+1.10%ClosedMarket Cap: $91.6M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
3.14
P/S
3.06
EV/EBITDA
42.37
DCF Value
$-13.90
FCF Yield
3.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
42.6%
Operating Margin
8.4%
Net Margin
-1.8%
ROE
-1.9%
ROA
-1.2%
ROIC
6.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $10.4M | 45.0% | $2.0M | $1.9M | $— | — |
| Q4 null | $7.6M | 38.2% | $-58.0K | $-2.8M | $— | — |
| FY null | $27.6M | 41.4% | $1.6M | $-1.0M | $— | — |
| Q3 null | $5.5M | 42.9% | $20.1K | $-139.7K | $— | — |
| Q2 null | $6.4M | 43.7% | $569.6K | $501.9K | $— | — |
| Q1 null | $8.1M | 41.6% | $1.1M | $1.4M | $— | — |
| Q4 null | $7.8M | 36.5% | $621.4K | $514.6K | $— | — |
| FY null | $26.5M | 30.0% | $-1.6M | $-2.2M | $— | — |
| Q3 null | $6.0M | 26.3% | $-574.9K | $-701.7K | $— | — |
| Q2 null | $5.5M | 22.5% | $-1.4M | $-1.5M | $— | — |
| Q1 null | $7.3M | 31.6% | $-300.1K | $-437.9K | $— | — |
| Q4 2023 | $5.1M | 24.7% | $-1.0M | $-1.1M | $-0.15 | — |